Elafibranor (INN, code name GFT505) is an experimental medication that is being studied and developed by Genfit for the treatment of cardiometabolic diseases including diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).
Elafibranor is a dual PPARα/δ agonist.
Administered to over 800 patients and healthy volunteers to date, elafibranor has demonstrated:beneficial properties for non-alcoholic steatohepatitis (NASH)
improvement of insulin sensitivity and glucose homeostasis
Phase 2b (GOLDEN) results were published online in Gastroenterology in February 2016 and will be fully available in the paper version in May 2016.
As of February 2016, elafibranor has completed 8 clinical trials and a phase III is in progress.
Efficacy on histological NASH parameters (steatosis, inflammation, fibrosis) in animal disease models — anti-fibrotic activities.
The absence of safety concern has been confirmed in a full toxicological package up to 2-year carcinogenicity studies and cardiac studies (in mice).